Table 3.

Drugs Currently in Phase 3 Clinical Trials for the Management of PBC

Drug	NCT	Mechanism of Action	Primary Endpoint
Seladelpar	NCT04620733	PPAR-delta agonist	ALP<1.67 ULN >15% reduction in ALP Total bilirubin <ULN
Saroglitazar	NCT05133336	PPAR alpha and gamma agonist	ALP<1.67 ULN >15% reduction in ALP Total bilirubin <ULN
Elafibranor	NCT04526665	PPAR-alpha and delta agonist	ALP<1.67 ULN >15% reduction in ALP Total bilirubin <ULN
Setanaxib	NCT05014672	NOX 1 and 4 inhibitors	ALP<1.67 ULN >15% reduction in ALP Total bilirubin <ULN
Linerixibat	NCT04950127	ASBT inhibitors	Monthly itch scores over 24 weeks